Lysosomal Substrate Accumulation Module

Module lysosomal_substrate_accumulation 3 disorders Pathograph 5

A conserved pathological module representing the shared core of the lysosomal storage diseases (LSDs): an inherited deficiency of a specific lysosomal hydrolase (or of a non-enzymatic protein/transporter essential for normal lysosomal function) blocks catabolism of a macromolecular substrate, which then accumulates undegraded within the lysosome. Progressive intralysosomal storage distends the organelle and impairs lysosome function, triggering a secondary cascade of autophagic-flux block, disturbed signalling, mitochondrial and calcium dysregulation. The affected cell type — often only a subset of cells determined by where the substrate is normally turned over — undergoes storage-cell transformation, cytotoxicity, and (in the CNS) neuroinflammation and neurodegeneration, producing progressive multi-organ disease. This conserved core is shared across sphingolipidoses, mucopolysaccharidoses, glycoproteinoses, glycogenoses (Pompe), and free-substrate transport defects. Individual disorder entries declare conformance via conforms_to on their pathophysiology nodes, substituting the disorder-specific deficient enzyme, stored substrate, and storage cell type while preserving the conserved deficiency -> accumulation -> lysosomal dysfunction -> cytotoxicity -> multisystem disease chain.

⚙

Pathophysiology Nodes

5 shared nodes are defined in this module.

◉

Cell Types

⇄

Biological Processes

Notes

This is a mechanism module, not a specific disease. Disorder entries reference individual nodes via conforms_to (e.g., "lysosomal_substrate_accumulation# Lysosomal Substrate Accumulation"). The module defines the expected pathophysiology structure; conforming nodes in disorder files should substitute the disorder-specific deficient gene/enzyme and stored substrate while preserving the conserved cascade. Key disorder-specific substitutions: Gaucher uses glucocerebrosidase (GBA1) deficiency and glucocerebroside storage in macrophage-derived Gaucher cells (CL:0000235); Tay-Sachs/Sandhoff use hexosaminidase deficiency and GM2 ganglioside storage in neurons (CL:0000540); Fabry uses alpha-galactosidase A deficiency and Gb3 storage in endothelium, podocytes, and cardiomyocytes; the mucopolysaccharidoses use specific glycosaminoglycan-degrading enzyme deficiencies and GAG storage; Pompe uses acid alpha-glucosidase deficiency and lysosomal glycogen storage in myofibers. Evidence here is drawn from cross-LSD reviews documenting the conserved cascade rather than any single disease; evidence_source is OTHER because these are reviews synthesizing data across multiple study types. The key conformance target is the central effector node "Lysosomal Substrate Accumulation".

↗

Used By Disorder Entries

Fabry disease via Decreased alpha-galactosidase A activity → Lysosomal Hydrolase or Cofactor Deficiency , Lysosomal Gb3 and lyso-Gb3 accumulation → Lysosomal Substrate Accumulation

Gaucher Disease via Glucocerebrosidase Deficiency → Lysosomal Hydrolase or Cofactor Deficiency , Glucocerebroside Accumulation in Macrophages → Lysosomal Substrate Accumulation

Tay-Sachs Disease via Hexosaminidase A deficiency → Lysosomal Hydrolase or Cofactor Deficiency , GM2 ganglioside accumulation in neurons → Lysosomal Substrate Accumulation

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence-backed metadata.

⚙

Pathophysiology

Lysosomal Hydrolase or Cofactor Deficiency

trigger

A monogenic loss-of-function defect reduces the activity of a specific acid hydrolase that degrades a macromolecular substrate within the lysosome, or of a non-enzymatic protein (activator, membrane transporter, or trafficking factor) required for normal lysosomal catabolism. The identity of the deficient enzyme/protein varies by disorder, but the consequence — loss of the catabolic step for a particular substrate — is the conserved trigger of the module.

macromolecule catabolic process link DECREASED

Used by disorders

Fabry disease as Decreased alpha-galactosidase A activity

Gaucher Disease as Glucocerebrosidase Deficiency

Tay-Sachs Disease as Hexosaminidase A deficiency

Downstream

Lysosomal Substrate Accumulation Loss of the catabolic step leaves the substrate undegraded, so it accumulates within the lysosome.

Lysosomal Substrate Accumulation

central effector

The substrate that can no longer be degraded accumulates undegraded within the lysosomal lumen. Storage is frequently restricted to the cell types in which that substrate is normally turned over in greatest quantity (e.g., macrophages for glucocerebroside, neurons for gangliosides), which patterns the organ-specific clinical picture. This intralysosomal accumulation is the central, defining effector event of every lysosomal storage disease and the key conformance target for disorder entries.

Used by disorders

Fabry disease as Lysosomal Gb3 and lyso-Gb3 accumulation

Gaucher Disease as Glucocerebroside Accumulation in Macrophages

Tay-Sachs Disease as GM2 ganglioside accumulation in neurons

Downstream

Autophagic-Lysosomal Dysfunction and Secondary Cascade Progressive storage distends the lysosome and impairs its function, initiating a secondary cellular cascade.

Autophagic-Lysosomal Dysfunction and Secondary Cascade

amplifier

Progressive lysosomal storage impairs core lysosome functions, blocking autophagic flux and disturbing membrane repair, exocytosis, lipid homeostasis, and signalling. Substrate accumulation is only the first event of a cascade that includes accumulation of secondary metabolites and impairment of cellular trafficking, cell signalling, mitochondrial function, and calcium homeostasis. This amplifying step converts a single catabolic block into broad cellular dysfunction.

autophagy link DYSREGULATED lysosome organization link DYSREGULATED

Downstream

Storage-Cell Cytotoxicity and Neuroinflammation Sustained lysosomal and autophagic dysfunction drives storage-cell transformation, cytotoxicity, and, in the CNS, neuroinflammation.

Storage-Cell Cytotoxicity and Neuroinflammation

effector

The affected cell becomes an engorged storage cell whose impaired autophagy and lysosomal dysfunction compromise viability, driving apoptotic death. In the central nervous system, impaired neuronal autophagy initiates neuronal damage and activates microglia and astrocytes, producing a neuroinflammatory response that amplifies neurodegeneration. The specific storage cell varies by disorder (lipid-laden macrophage, ganglioside-laden neuron, GAG-laden mesenchymal and neural cells), but the progression from storage to cytotoxicity and inflammation is conserved.

macrophage link neuron link

apoptotic process link INCREASED inflammatory response link INCREASED

Downstream

Progressive Multisystem and Neurodegenerative Disease Accumulated cytotoxicity across affected cell types produces progressive organ and nervous-system disease.

Progressive Multisystem and Neurodegenerative Disease

consequence

The lack of degradation and lysosomal storage perturbs cellular homeostasis and, in turn, damages multiple organ systems. The specific clinical pattern (hepatosplenomegaly, skeletal dysplasia, cardiomyopathy, renal disease, psychomotor regression) depends on which cell types store substrate, but the final common outcome of progressive, multisystem, often neurodegenerative disease is conserved across the lysosomal storage diseases.